|
Nov 29
|
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387
|
|
Nov 28
|
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
|
|
Aug 31
|
NanoViricides progressing well with new Covid study
|
|
Jun 29
|
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
|
|
Apr 25
|
NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
|